Trial Profile
Evaluate Patterns of relapse and prognosis in ALK+ Non-small cell lung cancer patients who received and failed in crizotinib therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2015
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Dec 2015 New trial record